Comparison of the epidemiology, profile of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodeficiency virus type 1

Lacerda, Heloísa Ramos; Medeiros, Luzidalva Barbosa de; Cavalcanti, Ana Maria Salustiano; Ximenes, Ricardo Arraes de Alencar; Albuquerque, Maria de Fátima Pessoa Militão de

doi:10.1590/s0074-02762007005000103

Cited by 8 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most previous studies have not found any significant difference between HIV-1 subtype and rates of CD4 increases after cART initiation [8]–[10], [13], [15], [17], [23]. In one, relatively small, study [14], CD4 increases at 24 months after cART initiation were lower for individuals with non-B subtypes, but this difference was mainly due to the lower baseline CD4 counts for those harboring subtype A.…”

Section: Discussionmentioning

confidence: 89%

“…The few studies that examined the effect of single subtypes were restricted to specific subtypes depending on the geographic region from which the study population was derived [15]–[17]. Taking advantage of CASCADE, a large international collaboration of seroconverter cohorts, we aimed to investigate the effect of specific HIV-1 subtypes on immunological and virological response to cART in persons living in high-income countries.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration

Touloumi

Pantazis

Chaix³

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundWe aimed to compare rates of virologic response and CD4 changes after combination antiretroviral (cART) initiation in individuals infected with B and specific non-B HIV subtypes.MethodsUsing CASCADE data we analyzed HIV-RNA and CD4 counts for persons infected ≥1996, ≥15 years of age. We used survival and longitudinal modeling to estimate probabilities of virologic response (confirmed HIV-RNA <500 c/ml), and failure (HIV-RNA>500 c/ml at 6 months or ≥1000 c/ml following response) and CD4 increase after cART initiation.Results2003 (1706 B, 142 CRF02_AG, 55 A, 53 C, 47 CRF01_AE) seroconverters were included in analysis. There was no evidence of subtype effect overall for response or failure (p = 0.075 and 0.317, respectively) although there was a suggestion that those infected with subtypes CRF01_AE and A responded sooner than those with subtype B infection [HR (95% CI):1.37 (1.01–1.86) and 1.29 (0.96–1.72), respectively]. Rates of CD4 increase were similar in all subtypes except subtype A, which tended to have lower initial, but faster long-term, increases.ConclusionsVirologic and immunologic response to cART was similar across all studied subtypes but statistical power was limited by the rarity of some non-B subtypes. Current antiretroviral agents seem to have similar efficacy in subtype B and most widely encountered non-B infections in high-income countries.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration

Touloumi

Pantazis

Chaix³

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Subtype D also showed a four-fold faster CD4 decline relative to subtype B [27]. Two studies from Brazil [24,28] found no difference between subtypes F and B with respect to the number of patients with undetectable VL [28] or virologic failure [24]. …”

Section: Resultsmentioning

confidence: 99%

“…Although data on outcomes such as undetectable VL levels were similar for subtypes B and F, data on death as an outcome was more frequent in subtype B [24,28]. Likewise, CD4 declines and virologic failures were faster in subtype D vs. (C, A and CRF02_AG) [27].…”

Section: Discussionmentioning

confidence: 99%

Do HIV‐1 non‐B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review

Bhargava

Cajas

Wainberg

et al. 2014

Journal of the International AIDS Society

View full text Add to dashboard Cite

There are 31 million adults living with HIV-1 non-B subtypes globally, and about 10 million are on antiretroviral therapy (ART). Global evidence to guide clinical practice on ART response in HIV-1 non-B subtypes remains limited. We systematically searched 11 databases for the period 1996 to 2013 for evidence. Outcomes documented included time to development of AIDS and/or death, resistance mutations, opportunistic infections, and changes in CD4 cell counts and viral load. A lack of consistent reporting of all clinical end points precluded a meta-analysis. In sum, genetic diversity that precipitated differences in disease progression in ART-naïve populations was minimized in ART-experienced populations, although variability in resistance mutations persisted across non-B subtypes. To improve the quality of patient care in global settings, recording HIV genotypes at baseline and at virologic failure with targeted non-B subtype-based point-of-care resistance assays and timely phasing out of resistance-inducing ART regimens is recommended.

show abstract

“…Another cohort study conducted in the UK showed no significant differences in the initial response to HAART for subtypes A, B, C, D, and CRF02_AG 9 . A Brazilian study evaluated the response of HIV-1 subtypes B and F and concluded that HAART was equally effective against these subtypes 12 . In a study in Spain, 79 ARV naïve patients of different ethnicities were evaluated as to the time to reach viral suppression and CD4+ T cell gain, with results suggesting a similar outcome for B and non-B subtypes 5 .…”

Section: Discussionmentioning

confidence: 99%

The Influence of Hiv-1 Subtypes C, Crf31_bc and B on Disease Progression and Initial Virologic Response to Haart in a Southern Brazilian Cohort

Nunes¹,

Matte²,

Dias³

et al. 2014

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Background: Although most HIV-1 infections in Brazil are due to subtype B, Southern Brazil has a high prevalence of subtype C and recombinant forms, such as CRF31_BC. This study assessed the impact of viral diversity on clinical progression in a cohort of newly diagnosed HIV-positive patients. Methods: From July/2004 to December/2005, 135 HIV-infected patients were recruited. The partial pol region was subtyped by phylogeny. A generalized estimating equation (GEE) model was used to examine the relationship between viral subtype, CD4+ T cell count and viral load levels before antiretroviral therapy. Hazard ratio (Cox regression) was used to evaluate factors associated with viral suppression (viral load < 50 copies/mL at six months). Results: Main HIV-1 subtypes included B (29.4%), C (28.2%), and CRF31_BC (23.5%). Subtypes B and C showed a similar trend in CD4+ T cell decline. Comparison of non-B (C and CRF31_BC) and B subtypes revealed no significant difference in the proportion of patients with viral suppression at six months (week 24). Higher CD4+ T cell count and lower viral load were independently associated with viral suppression. Conclusion: No significant differences were found between subtypes; however, lower viral load and higher CD4+ T cell count before therapy were associated with better response.

show abstract

Comparison of the epidemiology, profile of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodeficiency virus type 1

Cited by 8 publications

References 25 publications

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration

Do HIV‐1 non‐B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review

The Influence of Hiv-1 Subtypes C, Crf31_bc and B on Disease Progression and Initial Virologic Response to Haart in a Southern Brazilian Cohort

Contact Info

Product

Resources

About